Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications.
Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.
As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 23 | -0.20 Decreased by -53.85% | -0.18 Decreased by -11.11% |
| Mar 21, 23 | -0.15 Increased by +16.67% | -0.19 Increased by +21.05% |
| Nov 14, 22 | -0.20 Increased by +31.03% | -0.17 Decreased by -17.65% |
| Aug 10, 22 | -0.18 Increased by +21.74% | -0.16 Decreased by -12.50% |
| May 11, 22 | -0.13 Increased by +35.00% | -0.18 Increased by +27.78% |
| Feb 23, 22 | -0.18 Decreased by -80.00% | -0.26 Increased by +30.77% |
| Nov 10, 21 | -0.29 Decreased by -141.67% | -0.22 Decreased by -31.82% |
| Aug 11, 21 | -0.23 Decreased by -21.05% | -0.21 Decreased by -9.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 3.00 K Decreased by -25.00% | -25.06 M Decreased by -74.61% | Decreased by -835.33 K% Decreased by -132.81% |
| Dec 31, 22 | 4.00 K Increased by 0.00% | -18.25 M Decreased by -37.49% | Decreased by -456.15 K% Decreased by -37.49% |
| Sep 30, 22 | 4.00 K Increased by 0.00% | -24.71 M Decreased by -7.75% | Decreased by -617.65 K% Decreased by -7.75% |
| Jun 30, 22 | 4.00 K Increased by 0.00% | -18.78 M Decreased by -6.03% | Decreased by -469.40 K% Decreased by -6.03% |
| Mar 31, 22 | 4.00 K Increased by 0.00% | -14.35 M Increased by +8.19% | Decreased by -358.80 K% Increased by +8.19% |
| Dec 31, 21 | 4.00 K Increased by 0.00% | -13.27 M Decreased by -90.18% | Decreased by -331.77 K% Decreased by -90.18% |
| Sep 30, 21 | 4.00 K Increased by +33.33% | -22.93 M Decreased by -323.65% | Decreased by -573.20 K% Decreased by -217.74% |
| Jun 30, 21 | 4.00 K Increased by 0.00% | -17.71 M Decreased by -126.52% | Decreased by -442.73 K% Decreased by -126.52% |